The Road Beyond Frontline CDK4/6 Inhibitors in HR+/HER2– Metastatic Breast Cancer Examines Combinations

Erin Frances Cobain, MD, highlights the current role of endocrine therapy and CDK4/6 inhibitors in HR-positive, HER2-negative metastatic breast cancer.

Related Keywords

United States ,San Antonio ,Texas ,Michigan ,Ann Arbor ,American ,Erin Frances Cobain ,American Society Of Clinical Oncology Annual Meeting ,University Of Michigan Rogel Cancer Center ,University Of Michigan ,Breast Cancer Clinical Research Team ,Onclive Institutional Perspectives ,Michigan Rogel Cancer Center ,San Antonio Breast Cancer Symposium ,American Society ,Clinical Oncology Annual ,